Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients

Lactate dehydrogenase predicts combined progression‐free survival after sequential therapy with abiraterone and enzalutamide for patients with castration‐resistant prostate cancer

“…First, enzalutamide induces CYP3A4, an enzyme responsible for abiraterone metabolism; thus, abiraterone used after enzalutamide might be metabolized earlier. Indeed, a recent prospective study indicated a correlation between plasma trough levels of abiraterone and both PSA response and PFS . Second, the use of enzalutamide might be associated with increased frequency of AR mutations, thus likely resulting in loss of antitumor activity of abiraterone used after enzalutamide.…”

The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers

“…Carton et al looked at the PK/PD relationship AAFP abiraterone acetate fine particle, AUC 0-? area under the plasma concentration-time curve from time 0 extrapolated to infinite time, AUC 0-t area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration, C max maximum concentration, CV % coefficient of variation expressed as percent, n number of subjects included in the pharmacokinetic population for each treatment, SD standard deviation, T terminal elimination half-life, T max time of maximum concentration *Observed differences were statistically significant (P\0.001, analysis of variance) between fed and fasted conditions between abiraterone trough concentrations and prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer after 3 months of treatment [18]. Their results showed that the average plasma abiraterone trough concentration was significantly higher in PSA responders versus nonresponders when OAA was administered under fasted conditions.…”

A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer

“…Abiraterone acetate is a CYP17‐inhibitor used to treat metastatic castration resistant prostate cancer(mCRPC) . There is accumulating evidence that, in the clinically used dose, exposure correlates well with treatment outcome (2–4) and that a threshold for abiraterone C trough (8.4 ng ml −1 ) is correlated with prostate specific antigen (PSA) response during therapy . In our clinic, Therapeutic Drug Monitoring (TDM) of abiraterone is performed to support treatment, for example, in case of drug–drug interactions .…”